Insight Molecular Diagnostics Free Cash Flow 2014-2026 | IMDX
Insight Molecular Diagnostics free cash flow from 2014 to 2026. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
| Insight Molecular Diagnostics Annual Free Cash Flow | |
|---|---|
| 2025 | |
| 2024 | -21.23 |
| 2023 | -23.25 |
| 2022 | -49.91 |
| 2021 | -38.19 |
| 2020 | -27.21 |
| 2019 | -20.63 |
| 2018 | -11.68 |
| 2017 | -13.48 |
| 2016 | -7.63 |
| 2015 | -4.73 |
| 2014 | -1.17 |
| 2013 | -0.74 |
| Insight Molecular Diagnostics Quarterly Free Cash Flow | |
|---|---|
| 2026-03-31 | |
| 2025-12-31 | |
| 2025-09-30 | -18.35 |
| 2025-06-30 | -12.79 |
| 2025-03-31 | -6.17 |
| 2024-12-31 | -21.23 |
| 2024-09-30 | -15.64 |
| 2024-06-30 | -10.02 |
| 2024-03-31 | -3.85 |
| 2023-12-31 | -23.25 |
| 2023-09-30 | -18.56 |
| 2023-06-30 | -15.01 |
| 2023-03-31 | -8.30 |
| 2022-12-31 | -49.91 |
| 2022-09-30 | -39.46 |
| 2022-06-30 | -27.20 |
| 2022-03-31 | -14.84 |
| 2021-12-31 | -38.19 |
| 2021-09-30 | -30.72 |
| 2021-06-30 | -19.35 |
| 2021-03-31 | -10.68 |
| 2020-12-31 | -27.21 |
| 2020-09-30 | -20.90 |
| 2020-06-30 | -14.37 |
| 2020-03-31 | -6.91 |
| 2019-12-31 | -20.63 |
| 2019-09-30 | -14.43 |
| 2019-06-30 | -9.58 |
| 2019-03-31 | -6.73 |
| 2018-12-31 | -11.68 |
| 2018-09-30 | -9.22 |
| 2018-06-30 | -6.73 |
| 2018-03-31 | -2.76 |
| 2017-12-31 | -13.48 |
| 2017-09-30 | -10.13 |
| 2017-06-30 | -6.63 |
| 2017-03-31 | -3.31 |
| 2016-12-31 | -7.63 |
| 2016-09-30 | -5.03 |
| 2016-06-30 | -3.98 |
| 2016-03-31 | -2.18 |
| 2015-12-31 | -4.72 |
| 2015-09-30 | -2.55 |
| 2015-06-30 | -1.16 |
| 2015-03-31 | -0.18 |
| 2014-12-31 | |
| 2013-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.102B | $0.004B |
| Insight Molecular Diagnostics Inc. is a pioneering diagnostics technology company. Insight Molecular Diagnostics Inc., formerly known as Oncocyte Corporation, is based in NASHVILLE, Tenn. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $24.733B | 27.19 |
| Tempus AI (TEM) | United States | $7.677B | 0.00 |
| Hims & Hers Health (HIMS) | United States | $4.429B | 38.86 |
| Doximity (DOCS) | United States | $3.888B | 16.84 |
| IRhythm Holdings (IRTC) | United States | $3.724B | 0.00 |
| 10x Genomics (TXG) | United States | $2.973B | 0.00 |
| Privia Health (PRVA) | United States | $2.810B | 131.59 |
| Hinge Health (HNGE) | United States | $2.789B | 0.00 |
| Heartflow (HTFL) | United States | $2.311B | 0.00 |
| Omnicell (OMCL) | United States | $1.564B | 43.00 |
| Inspire Medical Systems (INSP) | United States | $1.555B | 20.94 |
| Enovis (ENOV) | United States | $1.405B | 7.40 |
| Butterfly Network (BFLY) | United States | $1.047B | 0.00 |
| Azenta (AZTA) | United States | $1.023B | 41.13 |
| Clover Health Investments (CLOV) | United States | $1.013B | 0.00 |
| Talkspace (TALK) | United States | $0.864B | 103.40 |
| Schrodinger (SDGR) | United States | $0.839B | 0.00 |
| Phreesia (PHR) | United States | $0.490B | 50.38 |
| Fulgent Genetics (FLGT) | United States | $0.429B | 0.00 |
| Standard BioTools (LAB) | United States | $0.345B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.322B | 0.00 |
| CapsoVision (CV) | United States | $0.311B | 0.00 |
| Senseonics Holdings (SENS) | United States | $0.279B | 0.00 |
| Claritev (CTEV) | United States | $0.269B | 0.00 |
| TruBridge (TBRG) | United States | $0.268B | 8.60 |
| Evolent Health (EVH) | United States | $0.260B | 0.00 |
| Carlsmed (CARL) | United States | $0.239B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.196B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.189B | 0.00 |
| CareCloud (CCLD) | United States | $0.115B | 8.18 |
| Nyxoah SA (NYXH) | Belgium | $0.111B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.101B | 0.00 |
| American Well (AMWL) | United States | $0.086B | 0.00 |
| Outset Medical (OM) | United States | $0.077B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.073B | 0.00 |
| Pulmonx (LUNG) | United States | $0.058B | 0.00 |
| 111 (YI) | China | $0.057B | 0.00 |
| NetraMark Holdings (AINMF) | Canada | $0.052B | 0.00 |
| Precipio (PRPO) | United States | $0.049B | 0.00 |
| HeartBeam (BEAT) | United States | $0.047B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.034B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.020B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.018B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.017B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.011B | 0.00 |
| Lunai Bioworks (LNAI) | United States | $0.009B | 0.00 |
| Zhongchao (ZCMD) | China | $0.008B | 0.00 |
| HeartSciences (HSCS) | United States | $0.007B | 0.00 |
| ITonic Holdings (ITOC) | China | $0.005B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.003B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.002B | 0.00 |
| PROFUSA (PFSA) | United States | $0.001B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.001B | 0.00 |